BCM
NAGE

Bayesian Capital Management’s Niagen Bioscience NAGE Stock Holding History

Bayesian Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,200
Closed -$104K – 578
2025
Q3 		$104K Sell
11,200
-3,300
-23% -$33.3K 0.02% 483
2025
Q2 		$209K Buy
14,500
+1,000
+7% +$9.88K 0.03% 455
2025
Q1 		$93.2K Buy
+13,500
New +$84.8K 0.02% 546

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bayesian Capital Management's NAGE Position: Q4 2025 in Review

Bayesian Capital Management sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 11,200 shares — an estimated $104K sold.

Bayesian Capital Management first reported a position in NAGE in Q1 2025 and held it in 3 quarters. The position peaked at $209K in Q2 2025. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

  • Bayesian Capital Management reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 11,200 Niagen Bioscience shares in Q4 2025, an estimated $104K.
  • Bayesian Capital Management first reported a position in Niagen Bioscience in Q1 2025 and held it in 3 quarters.
  • Bayesian Capital Management's Niagen Bioscience position peaked at $209K in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.